Cogent Biosciences announced additional clinical results from the SUMMIT trial showing bezuclastinib achieved a mean TSS reduction of -32.0 points at 48 weeks, with 99% of patients achieving >50% reduction in serum tryptase and 83% achieving normalization. The data demonstrates consistent symptomatic improvements across multiple organ systems and evidence of disease modification in NonAdvanced Systemic Mastocytosis patients. The company's NDA for bezuclastinib in NonAdvSM was submitted in December 2025, with an APEX NDA submission for advanced SM expected in 1H 2026.

Cogent Biosciences announced multiple poster presentations highlighting bezuclastinib results from the SUMMIT trial in NonAdvanced Systemic Mastocytosis patients at the 2026 AAAAI Annual Meeting in Philadelphia. The company previously submitted a New Drug Application to the FDA in December 2025 based on positive clinical data, following the drug's Breakthrough Therapy Designation.

The FDA granted Breakthrough Therapy Designation to Cogent Biosciences' bezuclastinib combined with sunitinib for gastrointestinal stromal tumors (GIST). The PEAK trial showed a 50% reduction in disease progression risk compared to sunitinib alone, with median PFS of 16.5 months versus 9.2 months. The combination was well-tolerated with no new safety concerns. Cogent expects to complete its NDA submission in April 2026 and initiate a Phase 2 trial for first-line GIST patients in mid-2026.

Cogent Biosciences announced that CEO Andrew Robbins will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The company is developing precision therapies for genetically defined diseases, with bezuclastinib as its most advanced program for systemic mastocytosis and gastrointestinal stromal tumors. Recent positive trial results showed a 57-80% objective response rate in advanced systemic mastocytosis patients.

Cogent Biosciences announced positive clinical trial results for bezuclastinib, demonstrating significant improvements in symptoms and disease markers for patients with nonadvanced systemic mastocytosis, with plans to submit a New Drug Application in December 2025.

Cogent Biosciences will participate in the Jefferies Global Healthcare Conference in London, presenting a live webcast about their precision therapies for genetically defined diseases, with a focus on their lead clinical program bezuclastinib.

Cogent Biosciences priced a public offering of 9,677,420 common stock shares at $31.00 per share and $200 million in convertible senior notes due 2031, expecting net proceeds of approximately $475.3 million to fund development activities and repay existing loans.

Cogent Biosciences will present data on bezuclastinib for NonAdvanced Systemic Mastocytosis at the ASH annual meeting, highlighting potential disease modification and introducing a new JAK2 V617F mutant-selective inhibitor program.

Cogent Biosciences presented preclinical data on its pan KRAS(ON) inhibitor CGT1263 at the 2025 AACR-NCI-EORTC International Conference, demonstrating potential best-in-class profile with plans to file an IND application in 2026.

Cogent Biosciences plans to raise approximately $200 million through a public offering of 22,222,223 common stock shares at $9.00 per share, with proceeds intended for product development and corporate purposes.

The gastrointestinal stromal tumor (GIST) market is expected to grow rapidly due to the launch of emerging therapies and increased healthcare spending globally. Key companies working on GIST treatments include Cogent Biosciences, IDRx, Deciphera Pharmaceuticals, and others.

Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news.